QDVG:XETRA:XETRA-iShares S&P 500 Health Care Sector UCITS ETF USD (Acc) EUR (EUR)

ETF | Others |

Last Closing

USD 9.541

Change

+0.06 (+0.66)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-0.48 (-1.07%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

+3.47 (+3.93%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.04 (-0.18%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.01 (-0.05%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.01 (+0.14%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.10 (+0.46%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

+0.12 (+1.02%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

+0.92 (+1.64%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.03 (+0.28%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.16 (+0.13%)

USD 12.26B

ETFs Containing QDVG:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.59% 31% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.59% 34% F 33% F
Trailing 12 Months  
Capital Gain -6.42% 15% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.42% 18% F 23% F
Trailing 5 Years  
Capital Gain 39.73% 45% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.73% 47% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 12.09% 74% C 73% C
Dividend Return 12.09% 73% C 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.94% 57% F 66% D+
Risk Adjusted Return 110.45% 93% A 94% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike